다제내성 폐결핵 환자의 베다퀼린과 델라마니드 동시, 장기간 사용 1예
Concurrent, Prolonged Use of Bedaquiline and Delamanid for Multidrug-Resistant Tuberculosis
황보현, 이세희, 조경욱, 심태선,
소속 상세정보
황보현 ( Hwangbo Hyun )
울산대학교 의과대학 서울아산병원 호흡기내과
이세희 ( Lee Se-Hee )
울산대학교 의과대학 서울아산병원 호흡기내과
조경욱 ( Jo Kyung-Uk )
울산대학교 의과대학 서울아산병원 호흡기내과
심태선 ( Shim Tae-Sun )
울산대학교 의과대학 서울아산병원 호흡기내과
Abstract
Bedaquiline and delamanid were recently approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Korea. A treatment duration of 24 weeks was established based on phase 2 clinical trial data, although the combined use of these two drugs is typically not recommended because it may exaggerate QT prolongation. Here, we present a case of prolonged treatment (48 weeks) with a combination of bedaquiline and delamanid for pulmonary MDR-TB. The patient had previously been diagnosed with extensively drug-resistant TB but had been left untreated for the past 9 years due to a shortage of effective drugs. A combination of bedaquiline and delamanid successfully treated MDR-TB, highlighting the potential efficacy of these drugs for patients with drug-resistant TB infections.
키워드
Bedaquiline; Delamanid; Tuberculosis; Multidrug-resistant
원문 및 링크아웃 정보
등재저널 정보